Dec 18 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's (3692.HK), opens new tab experimental oral drug to treat ...

Bearish flow noted in Merck (MRK) with 10,338 puts trading, or 1.1x expected. Most active are Jan-25 110 puts and Jan-25 115 puts, with total ...

Gerade mal in das mittlere Drittel des Dax schafft es heute die Aktie von der Merck KGaA mit einer Seitwärtsbewegung von ...

Merck just licensed a weight-loss drug candidate. There's reason to believe that the candidate could have a big edge. But, success is not guaranteed, and the program will take years to develop ...

Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion. Merck will pay Hansoh $112 million ...

Zum heutigen Handelsbeginn sind Signale der Investoren für das Hessischen Chemie- und Pharmaunternehmen negativ.

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion. Under the terms of the deal, the company will gain the exclusive global ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It garnered $16.7 billion in revenue and adjusted earnings of $1.57 per share ...

Ali Turan ist frischgebackener Anlagenmechaniker für Sanitär-, Heizungs- und Klimatechnik. Seit drei Jahren arbeitet er bei der Deffland und Merck GmbH und wurde bei der Deutschen Meisterschaft im ...

Darmstadt – Der Darmstädter Pharma und Technologiekonzern Merck stärkt sein Geschäft mit einer weiteren Übernahme. Der Dax-Konzern kauft das niederländische Unternehmen HUB Organoids ...

Merck & Co. Inc.’s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck MRK said a trial of the drug ...

Merck (MRK) announced the FDA has accepted the Biologics License Application, or BLA, for clesrovimab, the company’s investigational prophylactic long-acting monoclonal antibody designed to ...